LL-37 peptide
LL-37 peptide is a naturally occurring antimicrobial peptide that plays an important role in the innate immune system. It is part of a group of molecules known as antimicrobial peptides, which help the body defend against bacteria, viruses, and other pathogens.
LL-37 is derived from the precursor protein Cathelicidin antimicrobial peptide. It is produced by various cells of the immune system as well as epithelial tissues such as the skin and respiratory tract.
Because of its biological activity, LL-37 has been studied in research related to immune defense, wound healing, inflammation, and antimicrobial resistance.
Although it occurs naturally in the human body, synthetic LL-37 used in research is considered an experimental compound and has not been widely approved as a pharmaceutical medication.
How LL-37 peptide works
LL-37 functions as part of the body’s first line of defense against infection. Experimental studies suggest that the peptide may:
disrupt bacterial and microbial cell membranes, contributing to antimicrobial activity
modulate immune signaling pathways involved in inflammation and host defense
influence chemotaxis, helping recruit immune cells to sites of infection
support biological processes related to wound healing and tissue repair
In addition to its antimicrobial properties, LL-37 has been shown to interact with several signaling pathways that influence immune regulation and inflammatory responses.
Because of these mechanisms, researchers are investigating LL-37 in fields such as infectious disease research, dermatology, and immunology.
Clinical trials and evidence
Research involving LL-37 has been conducted mainly in laboratory studies and experimental clinical investigations. Studies have explored potential roles in areas such as:
antimicrobial defense mechanisms
experimental approaches to treating resistant infections
research into chronic wound healing and skin repair
investigations of immune regulation in inflammatory diseases
Some experimental findings suggest that antimicrobial peptides such as LL-37 may have therapeutic potential in certain medical contexts.
However, clinical development of LL-37 as a pharmaceutical drug remains limited, and most available information comes from preclinical research and early-stage clinical studies.
Possible side effects of LL-37 peptide:
Because LL-37 influences immune and inflammatory pathways, potential side effects observed in experimental contexts may include:
local irritation or inflammation
redness at the site of administration
headache
fatigue
Since synthetic LL-37 is primarily studied in experimental settings, its complete safety profile in humans has not been fully established.
Further research is required to better understand the long-term safety and potential risks associated with this peptide.